| Literature DB >> 15496927 |
Khaled Ali1, Antonio Bilancio, Matthew Thomas, Wayne Pearce, Alasdair M Gilfillan, Christine Tkaczyk, Nicolas Kuehn, Alexander Gray, June Giddings, Emma Peskett, Roy Fox, Ian Bruce, Christoph Walker, Carol Sawyer, Klaus Okkenhaug, Peter Finan, Bart Vanhaesebroeck.
Abstract
Inflammatory substances released by mast cells induce and maintain the allergic response. Mast cell differentiation and activation are regulated, respectively, by stem cell factor (SCF; also known as Kit ligand) and by allergen in complex with allergen-specific immunoglobulin E (IgE). Activated SCF receptors and high-affinity receptors for IgE (FcvarepsilonRI) engage phosphoinositide 3-kinases (PI(3)Ks) to generate intracellular lipid second messenger signals. Here, we report that genetic or pharmacological inactivation of the p110delta isoform of PI(3)K in mast cells leads to defective SCF-mediated in vitro proliferation, adhesion and migration, and to impaired allergen-IgE-induced degranulation and cytokine release. Inactivation of p110delta protects mice against anaphylactic allergic responses. These results identify p110delta as a new target for therapeutic intervention in allergy and mast-cell-related pathologies.Entities:
Mesh:
Substances:
Year: 2004 PMID: 15496927 DOI: 10.1038/nature02991
Source DB: PubMed Journal: Nature ISSN: 0028-0836 Impact factor: 49.962